Illumina, the biggest seller of gene sequencing machines, gave a weak outlook for sales in its central business in 2024. According to the company, genetic testing instruments will continue to see lacklustre demand all year. The tepid demand for tools and services to develop therapies and vaccines came from key markets like China. That weakness is amplified by a conservatism in spending from biotechnology firms in an environment of high interest rates.

Though consumable sales were solid and indicative of increased sequencing activity, CEO Jacob Thaysen called out a weakening demand for instruments in the face of a constrained funding landscape. As such, Illumina now expects its Core Illumina revenue to decline 2 per cent to 3 per cent year-over-year. Earlier, it had expected full-year revenue from the segment to be flat.

On an adjusted basis, Illumina forecasts a core segment per-share profit of $3.80 to $3.95 for 2024, which is near analyst expectations for a full-year adjusted profit of $3.91 per share for the entire company.

Illumina works under two reportable segments: Core Illumina and Grail. Grail, which was spun off on June 24, has been divested following its antitrust problems with both US and European regulators, plus huge opposition from activist investor Carl Icahn. The company had flagged a $1.47 billion goodwill impairment charge in the second quarter related to the Grail spin-off.

San Diego-based Illumina reported quarterly revenues of $1.11 billion for the second quarter, ahead of $1.08 billion that analysts had estimated. The company earned 36 cents a share on an adjusted basis during the quarter ended June 30, missing the average analyst estimate of 90 cents a share.

Illumina is focused on executing a strong consumable sales backdrop that will sustain it through a weakened instrument demand environment. These strategic decisions—like the divestiture of Grail—represent the company's efforts to refocus and renew its core operations within ongoing uncertainties in the markets.

Illumina, the biggest seller of gene sequencing machines, gave a weak outlook for sales in its central business in 2024. According to the company, genetic testing instruments will continue to see lacklustre demand all year.

Illumina, the biggest seller of gene sequencing machines, gave a weak outlook for sales in its central business in 2024. According to the company, genetic testing instruments will continue to see lacklustre demand all year. The tepid demand for tools and services to develop therapies and vaccines came from key markets like China. That weakness is amplified by a conservatism in spending from biotechnology firms in an environment of high interest rates. Though consumable sales were solid and indicative of increased sequencing activity, CEO Jacob Thaysen called out a weakening demand for instruments in the face of a constrained funding landscape. As such, Illumina now expects its Core Illumina revenue to decline 2 per cent to 3 per cent year-over-year. Earlier, it had expected full-year revenue from the segment to be flat. On an adjusted basis, Illumina forecasts a core segment per-share profit of $3.80 to $3.95 for 2024, which is near analyst expectations for a full-year adjusted profit of $3.91 per share for the entire company. Illumina works under two reportable segments: Core Illumina and Grail. Grail, which was spun off on June 24, has been divested following its antitrust problems with both US and European regulators, plus huge opposition from activist investor Carl Icahn. The company had flagged a $1.47 billion goodwill impairment charge in the second quarter related to the Grail spin-off. San Diego-based Illumina reported quarterly revenues of $1.11 billion for the second quarter, ahead of $1.08 billion that analysts had estimated. The company earned 36 cents a share on an adjusted basis during the quarter ended June 30, missing the average analyst estimate of 90 cents a share. Illumina is focused on executing a strong consumable sales backdrop that will sustain it through a weakened instrument demand environment. These strategic decisions—like the divestiture of Grail—represent the company's efforts to refocus and renew its core operations within ongoing uncertainties in the markets.

Illumina says slumping sales in core segment expected as demand softens, economy weighs

Illumina, the US genetic testing company has been fined by the European Union for a record 432 million euros (USD 476 million) on Wednesday (July 12). The fine has been imposed for closing its takeover&nbsp;of cancer test maker Grail without obtaining EU antitrust approval. &nbsp;

Illumina was forced to seek EU competition watchdog's approval in 2021 despite the deal fell short of the bloc's turnover threshold for scrutiny. Illumina has been fighting with the competition watchdog on several fronts since&nbsp;then.

In September 2022, the deal was eventually blocked. Regulators were concerned that Illumina, after acquiring Grail, would have an incentive to cut off Grail's rivals from accessing its technology to develop blood-based early cancer detection tests to compete with Grail.

The European Commission said that the size of the fine amounts to 10 per cent of Illumina's global revenue and it is the maximum allowed under EU merger rules for such infringements. The EC said that this underscored the seriousness of the offence and aimed to deter such conduct.&nbsp;

By closing the deal prematurely, Illumina was able to exercise a decisive influence over Grail, which it did, the EU enforcer said, calling the move unprecedented and a very serious infringement.

"If companies merge before our clearance, they breach our rules. Illumina and Grail knowingly and deliberately did so by implementing their tie-up as we were still investigating," EU antitrust chief Margrethe Vestager said in a statement.

For its active role in the infringement, Grail was given a symbolic 1,000 euro fine. This marks the first time a target company has been sanctioned.

<h2>Fine unlawful, disproportionate, says Illumina&nbsp;&nbsp;</h2>

Illumina has criticised the fine as "unlawful, inappropriate, and disproportionate". The company has said that it would appeal the penalty. It has set aside USD 458 million which represents 10 per cent of its consolidated annual revenue in fiscal year 2022.

"We closed the transaction in 2021 because there was no impediment to closing in the U.S. and the deal timeframe would have expired before the EC could reach a decision on the merits," the company said in a statement.

"The deal timeframe relied on the EC's public statements that it would not assert jurisdiction over mergers of this type until new guidelines were issued, yet the EC nonetheless asserted jurisdiction over the merger before issuing the promised guidelines."

Illumina has challenged the EU veto of the deal as well as its decision to examine the deal despite it not meeting the EU merger criteria and also the EU order to keep the Grail separate so that the deal con be unwound.

(With inputs from agencies)

You can now write for wionews.com and be a part of the community. Share your stories and opinions with us <a href="https://www.wionews.com/content-contribution-registration-form">here</a>.

WATCH WION LIVE HERE

<div class="ui-state-default" contenteditable="false">
<div class="twitter-block" draggable="false"><iframe allow="accelerometer; autoplay; encrypted-media; gyroscope; picture-in-picture" allowfullscreen="" frameborder="0" height="350" loading="”lazy”" src="https://www.wionews.com/live-tv/embed?autoplay=1&amp;mute=1" width="100%"></iframe></div>
<a class="close-mark close-div" href="#" id="jqclosemark">×</a></div>

&nbsp;

Illumina, the US genetic testing company has been fined by the European Union for a record 432 million euros (USD 476 million) on Wednesday (July 12). The fine has been imposed for closing its takeover of cancer test maker Grail without obtaining EU antitrust approval.

Illumina, the US genetic testing company has been fined by the European Union for a record 432 million euros (USD 476 million) on Wednesday (July 12). The fine has been imposed for closing its takeover of cancer test maker Grail without obtaining EU antitrust approval. Illumina was forced to seek EU competition watchdog's approval in 2021 despite the deal fell short of the bloc's turnover threshold for scrutiny. Illumina has been fighting with the competition watchdog on several fronts since then. In September 2022, the deal was eventually blocked. Regulators were concerned that Illumina, after acquiring Grail, would have an incentive to cut off Grail's rivals from accessing its technology to develop blood-based early cancer detection tests to compete with Grail. The European Commission said that the size of the fine amounts to 10 per cent of Illumina's global revenue and it is the maximum allowed under EU merger rules for such infringements. The EC said that this underscored the seriousness of the offence and aimed to deter such conduct. By closing the deal prematurely, Illumina was able to exercise a decisive influence over Grail, which it did, the EU enforcer said, calling the move unprecedented and a very serious infringement. "If companies merge before our clearance, they breach our rules. Illumina and Grail knowingly and deliberately did so by implementing their tie-up as we were still investigating," EU antitrust chief Margrethe Vestager said in a statement. For its active role in the infringement, Grail was given a symbolic 1,000 euro fine. This marks the first time a target company has been sanctioned. Fine unlawful, disproportionate, says Illumina Illumina has criticised the fine as "unlawful, inappropriate, and disproportionate". The company has said that it would appeal the penalty. It has set aside USD 458 million which represents 10 per cent of its consolidated annual revenue in fiscal year 2022. "We closed the transaction in 2021 because there was no impediment to closing in the U.S. and the deal timeframe would have expired before the EC could reach a decision on the merits," the company said in a statement. "The deal timeframe relied on the EC's public statements that it would not assert jurisdiction over mergers of this type until new guidelines were issued, yet the EC nonetheless asserted jurisdiction over the merger before issuing the promised guidelines." Illumina has challenged the EU veto of the deal as well as its decision to examine the deal despite it not meeting the EU merger criteria and also the EU order to keep the Grail separate so that the deal con be unwound. (With inputs from agencies) You can now write for wionews.com and be a part of the community. Share your stories and opinions with us here. WATCH WION LIVE HERE ×

EU slaps record $476 million fine on Illumina for Grail deal without antitrust approval

illumina

Illumina, News on Illumina, stories on Illumina, articles on Illumina, Illumina stories at Wion, Illumina news, Illumina latest news